Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Recruiting Phase 2 Trials for Ontorpacept (DB17116)

Also known as: Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

IndicationStatusPhase
DBCOND0131475 (Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05507541TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaTreatment